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Abstract P-glycoprotein (Pgp) represents the archetypal
mechanism of drug resistance. But Pgp alone cannot expel
drugs. A small but growing body of works has demon-
strated that the membrane biophysical properties are cen-
tral to Pgp-mediated drug resistance. For example, a
change in the membrane surface pressure is expected to
support drug–Pgp interaction. An interesting aspect from
these models is that under specific conditions, the mem-
brane is predicted to take over Pgp concerning the mech-
anism of drug resistance especially when the surface
pressure is high enough, at which point drugs remain
physically blocked at the membrane level. However it
remains to be determined experimentally whether the
membrane itself could, on its own, affect drug entry into
cells that have been selected by a low concentration of drug
and that do not express transporters. We demonstrate here
that in the case of the drug doxorubicin, alteration of the
surface pressure of membrane leaflets drive drug
resistance.
Keywords Drug resistance  Pharmacokinetic 
Membrane  Drug transporter  P-glycoprotein  MDR
Introduction
In 2007, the American Cancer Society report concluded
that cancer kills *7 m people a year worldwide (1 in 8
deaths). One of the major concerns in this field is that many
cancers fail to respond to chemotherapy, by acquiring
multi-drug resistance (MDR), to which has been attributed
the failure of treatment in over 90 % of patients with
metastatic cancer [1]. Furthermore, it is now recognized
that cancer aggressiveness, i.e. the metastatic potential of
tumours, is related to their resistance to chemotherapy
[2, 3].
One major form of resistance to chemotherapy has been
correlated with the presence of membrane molecular
‘‘pumps’’ that actively transport drugs out of the cell.
Historically, it was in 1973 that Dano Keld suggested that
the mechanism of resistance was due to an outward efflux
of drugs that ‘‘vacuum clean’’ drugs from cells [4]. This
hypothesis gained credence 3 years later when P-glyco-
protein (Pgp) was identified as a membrane protein over-
expressed in MDR cancer cells that actively extrude
membrane-embedded drugs [5]. Since then and further to
an important body of works the molecular basis of Pgp is
now defined with remarkable precision [6]. Although the
molecular model of Pgp has permitted a representation of
MDR in agreement with the usual concepts issued from the
field of biochemistry, how a single protein can expel
structurally different drugs is still poorly understood [7].
Accordingly, models of drug resistance were suggested to
complete the Pgp theory, assuming a fundamental role for
the cell membrane biophysical properties to sustain drug
pumping in resistant cells [8–11]. It is noteworthy that
under certain conditions the asymptotic forms of these
membrane-based theories can also explain drug resistance
without a pumping mechanism but solely by considering
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the biophysical properties of the membrane and related
interaction with drugs.
Suggesting the involvement of the cell membrane in
drug delivery, efficacy, or resistance is neither new nor a
mystery [12]. This is particularly true concerning the
membrane biomechanical properties as not only the basic
principles of pharmacokinetic consider as central the role
of surface pressure (or similarly surface tension) in the
transverse movement of drugs across the membrane but
also; the first seminal study on drug resistance performed
more than 40 years ago demonstrated the correlation
between the molecular weight (MW) of drugs and levels of
resistance [13], suggesting similarly a role for the surface
pressure [14]. The role of membrane surface pressure was
also investigated more recently using the Langmuir–
Blodgett technique and lipid monolayer film extracts from
sensitive or Pgp-expressing resistant cells [15]. It was
found that upon doxorubicin incubation, the surface pres-
sure develops more and is stable in extracts from Pgp-
expressing resistant cells, suggesting stronger interaction
between doxorubicin and lipids in this case.
Although a number of theoretical and experimental
results suggest that the cell membrane and its related
mechanical properties are paramount in drug resistance,
little (if any) has been done in living cells. The major
problem in this case is that transporters are also expressed
in drug resistant cells and from living cell studies it is
almost impossible to differentiate between pumping or
membrane effects. Only reconstituted systems for trans-
porters [16], or lipid extracts as above, are available to
study a particular parameter in drug resistance. However,
due to their complex nature cells can display major dif-
ferences with model systems [17].
To resolve this issue and determine whether the mem-
brane biomechanical properties can be fundamentally
involved in drug resistance, we have selected drug resistant
K562 cell (DRK562) with 10 nM doxorubicin over a per-
iod of 6 months. With such a low concentration of doxo-
rubicin no Pgp or ABCG2 were identified albeit resistance
to doxorubicin was measured. We demonstrate here that
mechanical effects associated with changes in the surface
pressures of membrane leaflets are indeed present in
DRK562 versus K562.
Materials and methods
Cell culture
K562 human erythroleukemia cell lines kindly provided
by Pluen [18]. Both K562 and DRK562 were separately
cultured in RPMI supplemented by 10 % FBS and
2 mM L-glutamine. Cells were maintained at 37 C in a
5 % CO2 atmosphere. DRK562 were further incubated
with a constant 10 nM of Doxorubicin. At confluence,
50 ml of media containing either K562 or DRK562 cells
were centrifuged at 1,200 rpm for 10 min to collect and re-
suspend the cell pellets into the desired volume of cell
culture media and in the required presence of doxorubicin
in the case of DRK562.
FACS
Mouse monoclonal primary antibodies against Pgp (clone
UIC2—abcam) or ABCG2 (clone 5D3—abcam) were used
on fixed cells with cold PFA4 % (w/v) for 30 min. Mem-
brane permeabilization was carried out using 0.05 % (w/v)
saponin for 45 min. 0.2 % BSA (w/v) was subsequently
used to block unspecific interactions. BSA was also present
at the same concentration when incubating Pgp antibodies
conjugated to phycoerythrin (Ex/Em = 488/578) or FITC
(Ex/Em = 488/519) for an hour with cells. Cells were then
subsequently washed three times in PBS and individual
fluorescence intensity of cells were analysed by cytofluo-
rimetry using a FACS (BD FACS Canto II). 10,000 events
were recorded for each sample at a medium flow rate and
subsequently analysed (FACSDiva Software).
Western blotting
Incubations were terminated by washing with ice-cold PBS
containing orthovanadate (Na3VO4) at 0.4 mM and whole
cell lysates prepared in lysis buffer [63.5 mM Tris_
HCl, pH 6.8, 10 % glycerol (vol/vol), 2 % SDS (wt/vol),
1 mM Na3VO4, 1 mM AEBSF, 50_g/ml leupeptin, 5 %
mercaptoethanol (vol/vol), and 0.02 % bromophenol blue
(wt/vol)]. The protein content of the cell lysate was mea-
sured using the Bradford test (Sigma) and a spectropho-
tometer (BMG FluoStar Optima), and equal quantities of
protein (30–60 lg/lane) were resolved using SDS-PAGE
(10, 7, or 4–12 %). The gel was then transferred onto
Hybond-P membrane (Amersham, Piscataway, NJ) that
was then blocked with non-fat dry milk or BSA at 5 % (wt/
vol) in PBS-Tween (1:1,000 vol/vol). For immunodetec-
tion, the ABCG2 (clone 5D3—abcam) monoclonal primary
antibody and the Pgp (ab98322—abcam) rabbit polyclonal
antibody were used at a concentration of 1:1,000 (vol/vol)
in PBS–Tween for 1 h. The membrane was subsequently
washed five times for 10 min each in PBS–Tween. HRP-
conjugated antibody was added at a concentration of
1:10,000 (vol/vol) in PBS–Tween for 1 h, and the mem-
brane was washed five times for 10 min each in PBS–
Tween before the chemiluminescence reaction was per-
formed using ECL Plus (Amersham). Protein levels were
examined using Hyperfilm (Amersham).
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Doxorubicin resistance levels deduced
from doxorubicin-induced cell death
Cells were stained using Dead Cell Apoptosis Kit with
Annexin V Alexa Fluor 488 (Ex/Em = 495/519 nm) and
Propidium Iodide (Ex/Em = 536/617 nm) (Invitrogen)
following manufacturer instructions. The FACS was
immediately used to determine cell viability and/or stage of
apoptosis. 10,000 events were recorded for each sample at
a medium flow rate and subsequently analysed (FACSDiva
Software). Data were compared against a logistic equation:
min þ ðmax  minÞ= 1 þ DOX=EC50ð ÞH
 
, to determine the
effective concentrations. In the last relation, ‘‘min’’ and
‘‘max’’ relate to the minimal and maximal percentages of
living cells, ‘‘Dox’’ is the doxorubicin concentration,
‘‘EC50’’ the effective doxorubicin concentration needed to
kill 50 % cells and H the Hill coefficient.
Doxorubicin diffusion across the cell membrane
Two-hundred millilitre of K562 and 200 ml of DRK562 were
centrifuged at 1,200 rpm for 10 min. Cell pellets (*250 ll
for each cell type) were collected and re-suspended in 300 ll
PBS. Note that a cell pellet of 250 ll contains about
125 million cells. The cells were washed two times with
300 ll PBS after centrifugation at 7.6 g for 30 s. Cells were
then subsequently plated onto a 96-well plate at constant ratio
of 10 ll pellet volume/90 ll PBS per well providing about
5 million cells per well. 100 ll PBS–doxorubicin were sub-
sequently injected per well at the desired concentration (no
doxorubicin was present in the injected solution for controls).
Fluorescence intensities were collected over time using a
fluorescence plate reader (BMG FluoStar Optima) using the
488 /620 nm excitation–emission wavelengths. When nee-
ded, triton X-100 was injected in wells at the concentration of
0.05 % (v/v). Due to the inherent difficulty to measure the
different quantum yields of doxorubicin in cells—that is a
prerequisite for an accurate description of how the fluores-
cence intensity changes along the time—a heuristic model
was devised instead. The normalized fluorescence intensities
(see Fig. 3a, b) were mono- or bi-phasic and we assumed that
they could be represented by the sum two classical ‘‘expo-
nential-type rise to the max’’ functions:
D~IðtÞ ¼ IðtÞ
I0
 1 ¼ a 1  ebt þ c 1  edt ; is: ð1Þ
where, I0, is the initial intensity. Matching experimental data
against Eq. 1 always provided good correlations
(R2 [ 0:980; Fig. 3c). After the initial extinction we found
associated with doxorubicin binding to cell membrane, the
initial parts of fluorescence recovery, i.e. ascending parts of
intensities, were supposed to be related to doxorubicin
crossing the membrane. Thus, determining the intensity
changes over time in this region provided the kinetics of
doxorubicin transmembrane diffusion. We therefore derived
the formula for dD~I=dt in the region that contains the flexion
point where mathematically: d2D~I=dt2
 
t¼t¼ 0. Note that,
t, is the time on the x axis at which the flexion point appears.
Thus, using Eq. 1 together with the later condition we
demonstrated that the kinetic of doxorubicin transverse
movement, km
km ﬃ dD
~I
dt
 
t¼t
¼ cd 1  d
b
 
exp  d
b  d ln 
ab2
cd2
  	
ð2Þ
Hoechst 33258 diffusion across the cell membrane
Similar steps as done above were followed prior to adding
2 ll of Hoechst (Ex/Em = 355/460) at the required con-
centrations in the 200 ll wells containing PBS–doxorubi-
cin and cells. The quantum yield of Hoechst changes
dramatically upon interacting with cells and it was possible
to measure its intensity over time using the fluorescent
plate reader. Hoechst intensity displayed two trends, a
strong exponential-like increase over short period of times
(*5 min) followed by a linear trend afterward (Fig. 4c). A
model was devised to take into consideration intensity
changes based on a two compartments model. We assumed
that the first increased was related to the amount of probes,
nmðtÞ, interacting with the membrane (compartment 1)
[19], written as:
dnm=dt ¼ k1ðNm  nmÞ ð3Þ
In this context, Nm, is the total amount of Hoechst
probes that can interact with the membrane and, k1, the
kinetic of interaction. We modelled the second trend as a
linear accumulation of probes from the membrane into the
cytosol (compartment 2), written as:
dnc=dt ¼ kmnm ð4Þ
In this last context, nc, is the total amount of Hoechst
probes accumulating into the cytosol and, km, the kinetic of
accumulation. As the quantum yield switched from near-
zero to very-high value intensities we assumed a linear
relationship between Hoechst intensity, IðtÞ, and Hoechst
interacting with cells, nm þ nc, such that:
IðtÞ nmðtÞ þ ncðtÞ ð5Þ
Using Eqs. 3, 4, and 5 lead to:
IðtÞNm kmt þ 1  km
k1
 
1  ek1t 
 	
ð6Þ
Using SigmaPlot software, experimental results were
compared against Eq. 6 (Fig. 4c, R2 [ 0.970 was the
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selection criteria) to deduce km for Hoechst. Given the
potential overlap between Hoechst emission and Dox
absorption we carried out further analysis to determine
whether FRET (fluorescence resonance energy transfer)
was taking place. However, we did not measure any FRET
levels in our experiments (data not shown).
DiBac4(3) diffusion across the cell membrane
Similar steps as done above were followed prior incubating
2 ll of DiBac4(3) (Ex/Em = 485/590) (Sigma) required
concentrations in the 200 ll wells containing PBS–doxo-
rubicin and cells. The quantum yield of DiBac4(3) changes
dramatically upon interacting with cells and it was possible
to measure its intensity after a 40 min period using the
fluorescent plate reader. Similarly done as above, no FRET
was detected between DiBac4(3) and doxorubicin.
Endocytosis measurement using FM210
Similar steps as done above were followed prior to incu-
bating 2 ll of FM210 (Ex/Em = 485/620) (Sigma) required
concentrations in the 200 ll wells containing PBS–doxo-
rubicin and cells. The quantum yield of FM210 changes
dramatically upon interacting with cells and it was possible
to measure its intensity over time using the fluorescent
plate reader. The slow increase in membrane endocytosis
allows one to measure directly the kinetic of endocytosis
with a one compartment model as described elsewhere
[20, 21]. Similarly done as above, no FRET was detected
between FM210 and doxorubicin.
Statistical analysis
In graphs or plots error bars represent the standard devia-
tion. The sign ‘‘*’’ denotes p value\0.05 between data. As
Fig. 7a contains many histograms, the data signification is
given literally directly within the legend. Number of rep-
licate varied between three and ten depending on the
experiment.
Results
Determination of doxorubicin sensitivity in K562
and DRK562 cell lines
To compare the ability of drugs to cross the membrane in
either resistant or sensitive cells we generated our own
K562 drug resistant cell line as described in the protocol
section. To address the level of resistance we measured the
level of cell death in the presence of an increasing con-
centration of doxorubicin using two markers of apoptosis,
firstly propidium iodide to probe membrane permeability
and secondly, annexin V to probe phosphatidylserine out-
ward translocation. The fluorescence intensity of propidium
iodide and annexin VI were measured by FACS analysis
(Fig. 1A). The results of the FACS showed populations of
cells in four quadrants of scatter diagrams. Cells in quadrant
4 (Q4) were considered to be viable and these data were
recorded for statistical analysis, but cells in other quadrants
which showed increased staining with either annexin V or PI
were either apoptotic or necrotic and therefore not consid-
ered viable. PI fluorescence histograms Fig. 1A also illus-
trate the presence of two distinct populations in the FACS
results, as defined by the positive (lower right panel) and
negative (upper panel) controls. Results were further con-
firmed by confocal microscopy (Fig. 1B). To determine the
effective concentrations (EC50), experimental results mea-
suring cell death were matched against a logistic equation
(see the fourth paragraph of ‘‘Materials and methods’’ sec-
tion) (Fig. 1C) in either sensitive or resistant case. As
expected we found K562 cells more sensitive to doxorubicin
(EC50 ¼ 186  80 nM; R2 ¼ 0:956) compared to home-
made resistant DRK562 (EC50 ¼ 250  5 nM; R2 ¼ 0:999).
Note that a difference in Hill coefficients, H, was found
between sensitive (H ¼ 2:1  1:2) and resistant (H ¼ 3:2
0:1) cells. In order to address Pgp expression following
doxorubicin selection we FACS-analysed and compared
K562 and DRK562. We found that only a very small fraction
of resistant cells express Pgp (Fig. 1D (a, b)). This result was
confirmed using western blot (Fig. 1D (b)). So the shift in
effective concentrations is unlikely to results from the single
expression of Pgp. In order to exclude another potent
doxorubicin transporter we also looked at ABCG2 expres-
sion levels and found no expression in our cells compared to
T47D cells [22] (Fig. 1E).
Membrane adsorptions of doxorubicin on sensitive
and resistant cells are similar at time zero but differ
at longer time scale
To assess the interaction of doxorubicin with the mem-
brane we measured the bleaching of doxorubicin fluores-
cence in the presence of cells (Fig. 2a). Based on the
fluorescent signal changes we estimated the binding affin-
ity of doxorubicin using a classical binding equation
(Fig. 2b). Note that doxorubicin self-quenching in solution
did not occur, or was negligible for the range of concen-
trations used (Fig. 2c). Thus, the changes in intensity were
truly related to doxorubicin interacting with cells.
As doxorubicin is quenched upon DNA interaction in
model vesicular systems, the drop in intensity in our cells
could be due to this specific interaction. However the use of
triton X-100 making the cell membrane more permeable
502 Cell Biochem Biophys (2013) 66:499–512
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allowed a further drop in intensity (Fig. 2d), suggesting that
the slow changes in the intensity profile observed along the
time (Fig. 2a) includes also the information regarding the
interaction between doxorubicin with the membrane.
Finally, we matched the results from Fig. 2b against a
classical-binding equation (similar to Eq. 8 see thereafter).
Results did not show huge differences between sensitive and
resistant cells: Ksens ¼ 6:4  1:3 lM (R2 ¼ 0:980) in drug
sensitive cells versus Kres ¼ 7:0  0:5 lM (R2 ¼ 0:994) in
drug resistant ones. Similarly the number of binding sites (B)
deduced differed only by 10 % Bsens=Bres ﬃ 1:10
(Bsens ¼ 3979  749 and Bres ¼ 3583  96).
Thus adsorptions of doxorubicin at time zero are similar
in either cell types. However, shortly after the incubation
data show that the drug will remain in the membrane for
longer periods of time in drug resistant cells compared to
sensitive ones (Fig. 3a, b)—see below.
The kinetic of doxorubicin’s transverse movement
across the membrane is inversely related to the amount
of doxorubicin adsorbed in the membrane
After the initial abrupt changes in doxorubicin fluorescence
we monitored the changes in fluorescence intensity as a
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Fig. 1 A Assessment of membrane permeability using propidium
iodide (PI-A, Y axis) and phosphatidylserine exposure using annexin-
V (Alex Fluor 488-A, X axis) of doxorubicin-treated (bottom) and non
treated (top) drug-resistant K562 (DRK562) cells. Note the shift in
fluorescence intensity between the doxorubicin-treated samples and
control. B Confirmation of (A) using fluorescence microscopy. The
green depicts annexin V in the outer leaflet of the cell membrane
whereas the orange–red colour shows propidium iodide interacting
with DNA. C Effect of doxorubicin concentration on cell survival for
an overnight treatment. The inset represents the impact on survival of
incubating cells in RPMI without FBS, no appreciable changes were
noted meaning that it is doxorubicin that kills cells and not the
experimental handling of cells. D FACS determination of Pgp
expression levels in drug resistant DRK562 and drug sensitive K562
cells. Inset (a) provides a magnification of the region of interest
selected by a square on the main figure. The legends containing the
suffix ‘‘-neg’’ correspond to negative controls (i.e., no Pgp antibody
incubated) whereas those containing the suffix ‘‘?Pgp-Ab’’ corre-
sponds to samples where the Pgp antibody was incubated. In either
case, we compared ‘‘sensitive’’ and ‘‘resistant’’ cell. Inset (b) shows
the protein expression levels of Pgp. A very thin band can be
distinguished for DRK562 confirming that some cells (but not all—
see inset (a)) express Pgp. E Determination of ABCG2 expression
levels in K562 and DRK562 compared to T47D cells
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function of time. We found that depending on doxorubicin
concentration, the intensity was biphasic. An initial
decrease followed by an increase in fluorescence (Fig. 3a,
b). Moreover, there was a clear difference between drug
sensitive and resistant cells. In particular, the fluorescence
recovery upon binding was slower in drug resistant cells
(arrows in Fig. 3a, b). We assumed that the biphasic
changes over short period of times, i.e. fluorescence
extinction and recovery within the first 30 min, were
related to drug binding the membrane (extinction) followed
by diffusion across the membrane to reach the cytoplasm
(recovery). This period was followed by a slow exponen-
tial-like increase that was assumed to be related to drugs
interacting with DNA (slow re-extinction).
It is notable from Fig. 3a and b that the kinetic changes
in fluorescence intensities were inversely related to the
extracellular concentration of doxorubicin. Thus, incorpo-
rating more doxorubicin into the cell membrane does not
mean better and/or quicker intracellular delivery of the
drug, but the contrary. As the amount of doxorubicin bound
to membrane is close between drug resistance and sensitive
cells (Fig. 2b) and that the fluorescence intensity of
doxorubicin varies linearly with the regime of concentra-
tions used (Fig. 2c), the changes observed were associated
with the ability of doxorubicin to cross the membrane. It is
also noteworthy that such ability to cross the membrane is
delayed in doxorubicin resistant cells compared to sensitive
cells (see arrows in Fig. 3a, b).
The slope of intensities of the fluorescence recovery
were then determined and plotted against doxorubicin
concentrations (Fig. 2d). We found overall that the kinetics
of fluorescence recovery were remarkably slow
 102 min1 in either cell type. This time scale is much
longer to what was found previously in vesicular model
systems [23]. Albeit the kinetic of fluorescence recovery
was slower in drug resistant cells compared to sensitive
ones, the direct effect of doxorubicin concentrations were
similar in either cell types (inset, Fig. 3d). Using Arrhe-
nius’ Law it was also possible to estimate a hypothetic
energy barrier required to cross the membrane as a function
of doxorubicin concentration (Fig. 3e). The possible role of
a variation in the energy barrier upon doxorubicin sug-
gested that membrane biophysical aspects may be taken
into consideration. In this context, a difference of  kBT
seems to make a difference between sensitive and resistant
cells. Note that in ‘‘kBT’’, kB stands for the Boltzmann’s
constant and T , for the absolute temperature.
Finally, as doxorubicin seems to affect its own entry,
doxorubicin influx into cells was determined (Fig. 3f) by
multiplying results from Fig. 2b (amount of doxorubicin
bound to membrane initially) by those of Fig. 3d (kinetics
of transverse movement). Figure 3f shows that doxorubicin
influx is, as expected, smaller in drug resistant cells com-
pared to drug sensitive ones and that both influx figures
drop significantly when the external concentration of
doxorubicin reaches 10 lM.
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Doxorubicin impacts negatively on the membrane
adsorption of Hoechst
Doxorubicin stays in membrane for long period of time. If
such a long residency time in membrane is responsible for
impeding doxorubicin influx, this should hold for any other
molecules. We decided to use Hoechst as its quantum yield
(i.e., fluorescence intensity) changes enormously when the
probe interacts with hydrophobic partner. Such property
facilitated modelling of Hoechst interacting with cells.
Doxorubicin was pre-incubated for 15 min before Hoechst.
In these conditions doxorubicin impeded Hoechst fluores-
cence in either sensitive or resistant cell lines (Fig. 4a, b) and
Eq. 6 (see Materials and methods section) was matched
against the experimental data (Fig. 4c). Albeit the amount of
Hoechst initially bound to drug resistant cells was slightly
higher (Fig. 4d), Hoechst binding to membrane decreased
similarly but identically in the two cell lines as doxorubicin
concentration increased (inset, Fig. 4d).
To determine whether pre-accumulation of doxorubicin in
membrane resulted in a decrease in binding energy of Hoechst to
the membrane, we assumed that the amount of Hoechst in
membrane, HOm, was a function of doxorubicin bound to the
membrane, Doxm, expressed by Arrhenius’ Law under the form:
HOm ¼ HO0m  ebDoxm=kBT ð7Þ
Membrane bound doxorubicin was previously related to
doxorubicin in solution, Dox, under the form:
Doxm ¼ B  Dox=ðK þ DoxÞ ð8Þ
Using the former and later equations it follows that:
lnðHOm=HO0mÞ ¼ ðb  BÞ=kBT  Dox=ðK þ DoxÞ ð9Þ
By challenging the data from Fig. 4c against a Lineweaver–
Burk plot, it was possible to determine whether doxorubicin
binding coefficients in drug sensitive or resistant cells were
similar to the ones determined previously from Fig. 2b. Only in
the case of resistant cells were the binding coefficients very
close, Kres ¼ 7:0 lM in Fig. 2b versus Kres ¼ 6:5 lMin
Fig. 4d or e. In sensitive cells, however, the binding
coefficients were clearly different: Ksens ¼ 6:4 lM in Fig. 2b
versus Ksens ¼ 3:0 lMin Fig. 4d or e.
The similarity between the binding coefficients for resistant
cells suggests that the impact on the membrane insertion of
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Hoechst is reflected by doxorubicin adsorption. Thus, the data
support a linear causal link in this case. On the contrary, the
lower binding coefficient in drug sensitive cells for Hoechst
suggests that the membrane is made more sensitive to Hoechst
by doxorubicin pre-incubation. As relatively less Hoechst can
integrate into the membrane following doxorubicin pre-
incubation in sensitive cells comparatively to drug resistant
cells, this suggests that the membrane is, in a sense, made more
‘‘rigid’’ to Hoechst insertion. Thus, the results may suggest
that the packing of lipid membrane (surface pressure) at least
in the outer leaflet and induced by the pre-adsorption of
doxorubicin in the membrane is likely to be central to the
membrane adsorption of Hoechst.
In conclusion, pre-adsorption of doxorubicin seems to
impact more strongly on Hoechst adsorption in sensitive
cells than in resistant cells.
Doxorubicin impacts positively on the transmembrane
kinetic of Hoechst
Contrary to doxorubicin, the kinetic of Hoechst’s trans-
verse movement increased as doxorubicin concentration
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increased (Fig. 4f). In this case, sensitive cells seemed to
be more responsive than resistant ones (inset, Fig. 4f). An
energy activation was then determined from Fig. 4f. It was
found that the energy drops rapidly by value  kBT for
micro-molar ranges of doxorubicin in drug sensitive cells
(Fig. 4g). Ten times more doxorubicin was needed to
observe a similar effect in drug resistant cells (inset,
Fig. 4g). In order to determine how the effects from Fig. 4f
were related to the amount of doxorubicin adsorbed in
membrane (Eq. 8), we assumed that the drop in the acti-
vation energy was proportional to the amount of doxoru-
bicin presents in the membrane. We carried out a similar
analysis using the same formula as for the case of Hoechst
above including a Lineweaver–Burk plot to determine Kres
and Ksens (Fig. 4h). In this context, we found Ksens ¼
1:7 lM and Kres ¼ 27:9 lM. As a result Hoechst’s transverse
movement is more impacted by doxorubicin pre-treatment
in sensitive cells (Ksens ¼ 1:7 lM) than in resistant cells
(Kres ¼ 27:9 lM).
If one devises the membrane as a two compartment
model namely outer and inner leaflets, the results suggest
strongly that in drug resistant cells Hoechst transverse
movement is impacted from the outer leaflet. On the con-
trary, both inner and outer leaflets seem important for drug
sensitive cells.
To appreciate the differential contribution of either
leaflets in drug sensitive and resistant cells endocytosis was
measured.
Fluid phase endocytosis is altered upon doxorubicin
incubation
Previous works have demonstrated that fluid phase
endocytosis is related to the differential surface tensions
between membrane leaflets [21]. In particular, it was
demonstrated (in K562 cells) that the kinetic of mem-
brane endocytosis is proportional to the tension asym-
metry [21]. Hence, measuring how endocytosis kinetics
are altered upon treatments provide an idea of how
membrane leaflets are affected. We carried out doxoru-
bicin pre-incubation for 15 min and incubated FM210 in
place of Hoechst (Fig. 5a).
It was found that doxorubicin has a strong effect in both
drug sensitive and resistant cells (Fig. 5b). These results
also confirmed that doxorubicin affects the membrane for
long period of times. The near linear drop in the kinetics of
endocytosis following doxorubicin incubation suggests that
doxorubicin accumulation in the membrane reverses the
endogenous difference in surface tensions. As the differ-
ence in surface tensions is the result of the lipid asymmetry
in these cells (K562), that is around *1–3 % [21, 24], the
slope from the figure allows one to determine that the
endogenous value of the lipid asymmetry decreases from
its initial value by *4–6 % per lM of doxorubicin
incubated.
DiBAC4(3) cellular accumulation is affected in drug
sensitive and resistant cells following doxorubicin
pre-treatment
As the result obtained could be related to changes in
membrane potential mediated by doxorubicin pre-incuba-
tion, DiBAC4(3) was used to probe the electrical field
across the membrane driven by the membrane potential of
cells. DiBAC4(3) is well characterised and accumulate in
cells with low membrane potential in an almost linear way
[25]. In order to avoid miss reading due to doxorubicin pre-
incubation and possible impact on the ability of DiBAC4(3)
to traverse the membrane, we focused on DiBAC4(3)
intracellular accumulation over long period of times, after
40 min incubation (Fig. 6). No significant differences were
found between cell lines with or without doxorubicin pre-
incubation, suggesting that the membrane potential is
unaltered due to doxorubicin incubation.
Statin and proton pump inhibitors sensitize drug
resistant cells to doxorubicin
In resistant cells that do express drug transporters, chemi-
cals can be used to re-sensitize cells to drugs. Some
chemicals interact directly with transporters but it is not
excluded that they could generate a dual effect interfering
with the membrane properties as well. Among these
chemicals statin-derived compounds commonly prescribed
to inhibit the rate limiting enzyme (HMG-CoA) of the
mevalonate pathway interact with Pgp [26] to resensitize
cells to drugs [27].
We decided to investigate how atorvastatin could
resensitize DRK562 to doxorubicin without involving drug
transporters. In order to compare the effect of atorvastatin
we used omeprazole and EIPA based on their ability to kill
cells by blocking proton export [28–30] and to resensitize
cells to drugs in drug transporter expressing [31] and non-
expressing cells [32]. By pre-incubating DRK562 cells in
the presence of these drugs for 24 h (step one), followed by
a further 24 h incubation with 50 nM doxorubicin (step
two). We found that 100 lM of atorvastatin is more effi-
cient than omeprazole at killing DRK562 cells but less
efficient than EIPA both employed at 100 lM (Fig. 7a).
We verified that at the later concentration omeprazole and
EIPA have an effect on proton export by measuring the
extracellular pH after the initial 24 h incubation with
DRK562 (Fig. 7b). To our surprise, we also measured a
similar trend in the presence of atorvastatin but that seems
to be less efficient than proton pump inhibitors (Fig. 7b).
Finally using Hoechst it was apparent that the transverse
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movement of Hoescht was twice as long with atorvastatin
suggesting a drop in membrane fluidity (Fig. 7c). It is
noteworthy that the effect of atorvastatin on cell death is
unlikely to be solely related to pH changes (Fig. 7b) as
otherwise omeprazole would have been more effective in
killing cells. Thus, membrane fluidity and related surface
pressure seem key for mediating cell death in the presence
or not of doxorubicin. Thus, when using drug resistance
sensitizers it is imperative to study membrane properties as
well as sensitizer interaction with Pgp.
Discussion
The potential role of membrane composition and related
biophysical properties has been suggested many times in
drug resistance and is reviewed in [12]. Albeit the mem-
brane has received much less attention than drug trans-
porters over the years, the profound entanglement between
the membrane biophysical properties and Pgp [8, 10, 11,
14, 33] calls for a clarification. In addition, there is now
enough evidence demonstrating that the surface pressure of
the membrane is an incidental ‘‘target’’ for some antineo-
plasic drugs [34–41] leading to the aggregation of apop-
tosis receptors to activate death pathways [36–38, 41–45].
This suggests that alteration of membrane fluidity may be
paramount in drug resistant cells. Finally, the recent dis-
covery that statin-derived drugs reverse drug resistance in
Pgp-expressing cells [46] is a further element pointing the
importance of the membrane in drug resistant cells.
To be able to work with cells and avoid the pitfall dis-
cussed in the introduction, we made our doxorubicin
resistant cells so that Pgp and ABCG2, another doxorubicin
transporter [22], were absent. Naturally these results do not
rule out the possibility that another doxorubicin transporter
that was not detected could be involved. However, this
point is unlikely as: (i) the intracellular influx of doxoru-
bicin does not increase—but decreases—as the external
concentration of doxorubicin increases (Fig. 3f), which is
contrary to what is expected from protein saturation of drug
pumps; (ii) in our home-made drug resistant cells Hoechst
is oblivious of the inner leaflet that should be central to
mediate drug resistance following the Pgp scheme assum-
ing a drug handling mechanism [6].
Herein, we measured how doxorubicin pre-incubation
affects its own entry into cells and interactions between
Hoechst and the membrane. Hoechst was chosen as it is
often used to demonstrate Pgp-mediated drug resistance
[47, 48].
We show here that with incubation of doxorubicin,
transverse movement slows down dramatically when the
concentration of the drug increase in either sensitive or
resistant cells. The increase of the residence time of
doxorubicin in the membrane affects Hoechst binding to
the membrane. However, the drop in Hoechst binding does
not affect Hoechst’s transverse movement as it crosses the
membrane more rapidly. It seems that doxorubicin pre-
incubation helps Hoechst to traverse the membrane. A very
simple idea could be that a higher surface pressure from the
outer leaflet due to doxorubicin pre-incubation could push
Hoechst to traverse the membrane. The pushing mecha-
nism can be imaged as an olive stone (the drug) pressed
between two fingers (the lipids from the outer leaflet) and
pushed away (across the membrane).
This model seems to stand out. Indeed, it is unlikely that
an increase in global membrane fluidity induced by doxo-
rubicin pre-incubation explain the ‘‘lubrication’’ observa-
tion, as an increase in fluidity should have facilitated Hoechst
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binding. Furthermore, this ability of doxorubicin to facilitate
Hoechst entry does not seem to be correlated to the mem-
brane potential of cells and related electromotive forces [49],
as drug sensitive cells that are the most affected by doxoru-
bicin do not show any appreciable changes in their mem-
brane potential further to doxorubicin pre-incubation. The
one biophysical parameter that is then left is the differential
packing of lipids across the membrane. Accordingly, we also
found that endocytosis is affected by doxorubicin in drug
sensitive and resistant cells.
In this context and from results concerning Hoechst
binding and transverse movement it is possible to estimate
the resting membrane tension prior to incubating doxoru-
bicin. In these conditions, in the expression of HOm (Eq. 7)
the parameter b would be expressed as: b ¼ r aDox;
where r is the tension and aDox the cross-section of
doxorubicin. As for drugs small enough the molecular
weight (MW) is proportional to the molecular volume it
follows: aDox  pð3MWDox=4pÞ2=3. Knowing the MW of
doxorubicin, it is thus possible to determine: rsens  5 
103 mN=m and rres  7  103 mN=m. The later values
are similar to what is found ( 3  103 mN/m) when cells
have large reservoir of membrane [50, 51] and a large
reservoir of membrane is expected for these cells [17, 21].
Accordingly the surface tension of the outer leaflet of
sensitive cells would be lower than in drug resistant cells.
This could explain the drop in Hoechst binding initially
prior to incubating doxorubicin. Note that the values found
are higher than the thermal value of the surface tension
needed to impede the transverse movement of doxorubicin
(kBT=aDox  2  104 mN=m) and thus the results above
are therefore coherent with a potential physical effect.
Moreover, our energy values related to drug–membrane
interaction are much higher than those linked to electro-
motive forces previously involved in drug resistant cells,
see ‘‘Discussion’’ in [8]. Hence, the underlying physical
mechanism must be central to drug delivery.
One point needs to be resolved, however. Let us suppose
that the outer leaflet is altered between drug sensitive and
resistant cells as suggested. If that is the case why only a
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marginal effect is observed on doxorubicin adsorption
between cell lines (Fig. 2b)? The answer comes from a
comparison between Figs. 3d and 4f. In these, the transverse
movement kinetic in control conditions is ten times longer
for doxorubicin than Hoechst. This seems to suggest that
doxorubicin has stronger affinity with the cell membrane
compared to Hoechst. Therefore, doxorubicin adsorption
would be dictated chiefly by its hydrophobic character hence
the lack of drastic differences between binding coefficients
in sensitive and resistant cells (Fig. 2b).
Finally one can interpret the results concerning the
kinetics of endocytosis as a consequence of changes in the
differential packing of lipids across the membrane. It was
demonstrated in K562 drug sensitive cells that the differ-
ence in surface tensions—i.e., the differential packing of
lipids across the membrane—is around Drsens  9 
104 mN=m [21]. As the kinetic of membrane endocytosis
measured is proportional to the difference in surface ten-
sions [17], this would mean that the same endogenous
difference in surface tensions in drug resistant cells should
be Drres  5  104 mN=m. The later value is relatively
close to the thermal value of the surface tension needed to
impede doxorubicin that in turn could explain why Hoechst
is more or less oblivious of the inner leaflet in these
resistant cell (recall that Kres  27:9 lM). Albeit a similar
conclusion could be applied in theory to drug sensitive
cells—namely that the inner leaflet should have a marginal
impact on the drug transverse movement since
Drsens\rsens—this is not confirmed experimentally (recall
that Ksens  1:7 lM). Therefore, mechanisms other than
those involving the membrane mechanical properties are
very likely involved in this case. This fixes a definitive
limit to the ‘‘olive stone’’ model that seems to be only
coherent in drug resistant cells and underline the appro-
priateness of using living cellular systems to study drug
resistance.
It is also important to underline that our system does not
express Pgp and therefore our results cannot be fully trans-
ferred to Pgp-expressing cells. Furthermore, it is important to
emphasize that we did not find an increase in endocytosis
contrary to what was measured in Pgp-expressing cells [12].
To conclude we suggest here that the ability of chemi-
cals to cross the membrane rely on the energy difference
between outer and inner leaflets and that incubation of drug
chemicals would affect this difference resulting in nonlin-
ear complications. Finally, a clearer understanding of the
physical biology of MDR is necessary to improve and
initiate new therapeutic strategies.
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